0001104659-13-059258.txt : 20130802 0001104659-13-059258.hdr.sgml : 20130802 20130802111402 ACCESSION NUMBER: 0001104659-13-059258 CONFORMED SUBMISSION TYPE: 425 PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20130802 DATE AS OF CHANGE: 20130802 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: OPTIMER PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001142576 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330830300 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 425 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33291 FILM NUMBER: 131005245 BUSINESS ADDRESS: STREET 1: 101 HUDSON STREET STREET 2: SUITE 3501 CITY: JERSEY CITY STATE: NJ ZIP: 07302 BUSINESS PHONE: (201) 333-8819 MAIL ADDRESS: STREET 1: 101 HUDSON STREET STREET 2: SUITE 3501 CITY: JERSEY CITY STATE: NJ ZIP: 07302 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: CUBIST PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000912183 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 223192085 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 425 BUSINESS ADDRESS: STREET 1: 65 HAYDEN AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 781-860-8660 MAIL ADDRESS: STREET 1: 65 HAYDEN AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 425 1 a13-17558_9425.htm 425

 

 

Filed by Cubist Pharmaceuticals, Inc.

 

Pursuant to Rule 425 under the Securities Act of 1933, as amended

 

Subject Company: Optimer Pharmaceuticals, Inc.

 

Exchange Act Commission File No: 001-33291

 

 

 

 

 


 

Date

 

Dear Dr. XXX;

 

Earlier this week, Cubist announced our planned acquisitions of both Trius Therapeutics and Optimer Pharmaceuticals.  As a key infectious disease expert, we thought it important to convey this information to you directly.

 

The prospects of continuing the development and potential commercialization of tedizolid (Trius) and the marketing of DIFICID (Optimer) reaffirms Cubist’s mission to provide therapies for seriously ill patients treated in and around the hospital setting.

 

Assuming the successful completion of the planned acquisitions and the success of our combined late stage pipeline, Cubist will contribute significantly towards the goal set by IDSA in their “10 by ’20” program for 2020.

 

We are excited about building the Cubist infectious disease portfolio and look forward to meeting with you soon.

 

Sincerely;

 

Lorianne K. Masuoka, M.D.

Senior Vice President, Clinical Development and Medical Affairs, and Chief Medical Officer

 

Peggy McKinnon, PharmD

Sr. Director, Field Medical Affairs

 

Cubist Pharmaceuticals, Inc.
65 Hayden Avenue
Lexington, MA  02421